Compare KMB & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMB | INSM |
|---|---|---|
| Founded | 1910 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.5B | 41.2B |
| IPO Year | N/A | 2000 |
| Metric | KMB | INSM |
|---|---|---|
| Price | $103.09 | $205.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 19 |
| Target Price | $129.58 | ★ $178.71 |
| AVG Volume (30 Days) | ★ 6.2M | 2.7M |
| Earning Date | 10-30-2025 | 10-30-2025 |
| Dividend Yield | ★ 4.89% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.91 | N/A |
| Revenue | ★ $19,724,000,000.00 | $447,022,000.00 |
| Revenue This Year | N/A | $43.10 |
| Revenue Next Year | $3.10 | $128.25 |
| P/E Ratio | $17.42 | ★ N/A |
| Revenue Growth | 11.62 | ★ 30.34 |
| 52 Week Low | $99.22 | $60.40 |
| 52 Week High | $150.45 | $212.75 |
| Indicator | KMB | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 36.41 | 61.95 |
| Support Level | $101.76 | $202.68 |
| Resistance Level | $110.03 | $208.81 |
| Average True Range (ATR) | 2.14 | 6.31 |
| MACD | 0.54 | -1.21 |
| Stochastic Oscillator | 15.11 | 59.86 |
With more than half of its sales from personal care and another third from consumer tissue products, Kimberly-Clark is a leading manufacturer in the tissue and hygiene realm. Its brand mix includes Huggies, PullUps, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates in the professional segment, partnering with businesses to provide safety and sanitary offerings for the workplace. Kimberly-Clark generates just over half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America. It intends to add Kenvue's consumer health portfolio to its mix in the second half of calendar year 2026.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.